The drug-funding agency estimated that 1200 patients would benefit this year, rising to more than 5000 annually after 2030.

Pharmac currently funds venetoclax for a different type of blood cancer called chronic lymphocytic leukaemia, and funds upadacitinib for some people with rheumatoid arthritis. Azacitidine is currently ...

The European Commission (EC) has granted marketing authorization to Rinvoq (upadacitinib; 15mg, once daily), from US pharma ...

AbbVie’s Rinvoq (upadacitinib) has been granted marketing authorisation by the European Commission (EC) to treat giant cell ...

The EC has granted marketing authorisation for AbbVie's once-a-day treatment Rinvoq (upadacitinib) 15mg for adults with GCA.

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

C disinfection cabinet market with its SaniUV-Cubetm, designed to quickly neutralize bacteria, mold, and viruses on many small items. It is constructed from stainless steel for extreme ...

April 3 (Reuters) - AbbVie (ABBV.N), opens new tab on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition expenses related to milestone ...

Upadacitinib at a dose of 15 mg showed superiority ... with the full text of this article at NEJM.org. Supported by AbbVie. Disclosure forms provided by the authors are available with the full ...

Raymond James initiated coverage of AbbVie Inc (NYSE:ABBV) with an Outperform rating and $177 price target in a note ...